What is Century Therapeutics Inc (IPSC) stock price today?

Century Therapeutics Inc (IPSC) currently trades at $2.20 per share. The stock has a market capitalization of $396.78M and a P/E ratio of —x.

Is IPSC stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Century Therapeutics Inc has a Smart Value Score of 27/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

What is Century Therapeutics Inc's revenue and earnings?

Century Therapeutics Inc has trailing twelve-month (TTM) revenue of $109.16M with profit margins of -8.78%. Earnings per share (EPS) is $-0.14.

IPSC

Century Therapeutics Inc

NASDAQ: IPSC · HEALTHCARE · BIOTECHNOLOGY

$2.20

+0.00% today

Updated 2026-04-29

Market cap

$396.78M

P/E ratio

—

P/S ratio

3.64x

EPS (TTM)

$-0.14

Dividend yield

—

52W range

$0 – $3

Volume

1.3M

Market cap

$396.78M

P/E ratio

—

P/S ratio

3.64x

EPS (TTM)

$-0.14

Dividend yield

—

52W range

$0 – $3

Volume

1.3M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

5.3

Growth

C+

5.0

Quality

C+

2.0

Profitability

5.0

Valuation

C+

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →200 stocks currently score above 75

Price targets

Analyst target

$3.67

+66.68%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy1 Buy1 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

Insufficient data

Risks

- Thin margins at -8.78%

- Negative free cash flow $-16.39M

- Revenue declining -100.00% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$5.20M	$2.23M	$6.59M	$109.16M	$109.16M
Net income	$-130.93M	$-136.67M	$-126.57M	$-9.58M	$-19.18M
EPS	—	—	—	—	$-0.14
Free cash flow	$-16.55M	$-102.08M	$-110.29M	$-104.72M	$-16.39M
Profit margin	-2,518.41%	-6,115.12%	-1,920.87%	-8.78%	-8.78%

Recent insider activity

Date	Insider	Type	Shares	Price
2026-04-01	COWAN, CHAD	Sale	1,365	$2.19
2026-03-12	RUSSOTTI, GREGORY	Sale	10,076	$2.55
2026-03-12	CARR, DOUGLAS	Sale	7,043	$2.55

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
IPSC	$396.78M	27	5.3	2.0	5.0	5.0	—	Avoid
LLY	$789.69B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.64B	59	4.7	9.0	3.3	6.0	-41.97%	Buy
ABBV	$351.47B	63	4.0	8.0	4.7	5.0	-24.92%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Century Therapeutics Inc trades at $2.20. Our Smart Value Score of 27/100 indicates the stock is weak. TTM revenue stands at $109.16M. with profit margins at -8.78%.

Frequently asked questions

What is Century Therapeutics Inc's stock price?

Century Therapeutics Inc (IPSC) trades at $2.20.

Is Century Therapeutics Inc overvalued?

Smart Value Score 27/100 (Grade F, Strong Sell).

What is the price target of Century Therapeutics Inc (IPSC)?

The analyst target price is $3.67, representing +66.7% upside from the current price of $2.20.

What is Century Therapeutics Inc's revenue?

TTM revenue is $109.16M.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio3.64x

ROE-5.98%

Beta1.67

50D MA$2.31

200D MA$1.21

Shares out0.18B

Float0.10B

Short ratio—

Avg volume1.3M

Performance

1 week-10.02%

1 month+8.37%

3 months-6.78%

YTD+121.15%

1 year—

3 years—

5 years—

Compare

IPSC vs LLY →IPSC vs JNJ →IPSC vs ABBV →Stock screener →